Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 568

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 568
---
 negative profit share amount recorded for CSL Vifor’s negative net sales for the second quarter of 2024 and $0.6 million due to Patheon for minimum manufacturing orders in 2024. Restructuring Expenses

| ​                      
 ​                      
 ​                      | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            
 Dollar amounts in thousands     |   |     |   | ​ | ​ | 2023 |   |   |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​   
 ​   | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |       |   | ​ | ​ | 2023 |   |   |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​   
 ​   | ​ 
 ​ | ​ 
 ​ 
 ​ |
|:-----------------------|:--|:--|:--------------------------------|:--|----:|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:---------|:--|:----|:--|:--|:--|:-------------------------------|:--|------:|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:---------|:--|:----|:--|:--|
| Restructuring expenses | ​ | ​ | ​                               | $ | 707 | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ | ​ | ​                              | $ | 5,689 | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ |

**328

TABLE OF CONTENTS

For the three months ended September 30, 2024, restructuring expenses were $0.7 million, which were related to the additional workforce reductions in the third quarter of 2024. There were no restructuring expenses recorded during the three months ended September 30, 2023. For the nine months ended September 30,